Your session is about to expire
← Back to Search
Eculizumab for Thrombotic Microangiopathy
Study Summary
This trial is testing whether a drug called eculizumab can help people with a complication from hematopoietic stem cell transplantation (HCT) called thrombotic microangiopathy (TMA). The investigators think that eculizumab might help people with TMA to live longer.
- Thrombotic Microangiopathy
- Multiple Organ Dysfunction Syndrome
- Atypical Hemolytic Uremic Syndrome
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2011 Phase 4 trial • 7 Patients • NCT00867932Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Is there still an opportunity for enrolment in this experiment?
"At this time, this research trial is not currently recruiting. The study was initially publicized on August 3rd 2018 and its details were updated November 23rd 2022. For individuals interested in participating in similar studies there are 1531 trials that centre around thrombotic microangiopathies, as well as 13 separate experiments employing Eculizumab therapy seeking participants."
What safety considerations must be taken into account when administering Eculizumab?
"The safety of Eculizumab is estimated to be a 2, as it has been tested in Phase 2 trials and some initial evidence of its security exists but there are no studies that confirm efficacy."
How extensive is the scope of this research study?
"Unfortunately, this clinical trial is not open for recruitment at the present moment. It was originally posted on August 3rd 2018 and recently updated on November 23rd 2022. If you are interested in other medical experiments concerning thrombotic microangiopathies, there are presently 1531 options available; 13 of these involve Eculizumab as a treatment option."
Are there other precedents of employing Eculizumab in clinical research?
"Currently, there are 8 Phase 3 trials and 5 additional clinical studies exploring eculizumab. Whittier is the epicentre for these investigations with a total of 594 sites participating in all 13 active tests."
What medical conditions is eculizumab traditionally employed to address?
"Eculizumab is an efficient treatment option for patients suffering from myasthenia gravis, generalized neuromyelitis optica and paroxysmal nocturnal hemoglobinuria (PNH)."
Is this medical trial unique in its methodology?
"Eculizumab has been under clinical scrutiny since 2016, when it was first tested in a trial funded by Alexion Pharmaceuticals. This initial study involving 270 participants led to the drug being approved for Phase 3 trials and today there are 13 ongoing tests of Eculizumab spanning 121 cities and 42 nations."
Share this study with friends
Copy Link
Messenger